The PC9 and HCC827 cells were utilized as EGFR-mutant cell lines of NSCLC, and 2 μM erlotinib could result in a decrease of 50% cell viability (Figure 1(a)). This evidence concerns the gene EGFR and non-small cell lung carcinoma.